{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T08:45:35Z","timestamp":1770799535095,"version":"3.50.0"},"reference-count":114,"publisher":"Bentham Science Publishers Ltd.","issue":"3","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>As research on upper tract urothelial carcinoma (UTUC) has deepened, the\nvalue of biomarkers in the prognostic evaluation of UTUC has been gradually highlighted.\nAs a high-grade epithelial tumor derived from the renal pelvis or ureter, UTUC has a\nsignificant prognostic challenge to patients, given its high invasiveness and recurrence\nrate for the formation of post-operative bladder cancer. To better predict the recurrence\nand metastasis risk of UTUC, this article provides a comprehensive review of hematologic,\nurologic, genetic, and histologic biomarker studies on the prognostic assessment of\nUTUC. This study covers a broad range of different kinds of biomarkers, as shown in\nthe graphical abstract. By systematically analyzing these biomarkers, we will have a better\nunderstanding of the biological features of UTUC, and it will provide more comprehensive\nand accurate information for its prognostic assessment. This will not only help\nclinicians develop more precise treatment strategies, but also provide patients with more\npersonalized rehabilitation recommendations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0109298673339558250123110322","type":"journal-article","created":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T05:51:28Z","timestamp":1739253088000},"page":"586-604","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["New Advancements in Prognostic Biomarkers for Upper Tract Urothelial Carcinoma"],"prefix":"10.2174","volume":"33","author":[{"given":"Xiaotong","family":"Shi","sequence":"first","affiliation":[{"name":"Department of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, P.R.China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guodong","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, P.R.China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","volume":"71","author":"Siegel R.L.","year":"2021","unstructured":"Siegel R.L.; Miller K.D.; Fuchs H.E.; Jemal A.; Cancer statistics, 2021. CA Cancer J Clin  2021,71(1),7-33","journal-title":"CA Cancer J Clin"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.eururo.2012.02.030","volume":"62","author":"Lughezzani G.","year":"2012","unstructured":"Lughezzani G.; Burger M.; Margulis V.; Matin S.F.; Novara G.; Roupret M.; Shariat S.F.; Wood C.G.; Zigeuner R.; Prognostic factors in upper urinary tract urothelial carcinomas: A comprehensive review of the current literature. Eur Urol  2012,62(1),100-114","journal-title":"Eur Urol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.eururo.2023.03.013","volume":"84","author":"Roupr\u00eat M.","year":"2023","unstructured":"Roupr\u00eat M.; Seisen T.; Birtle A.J.; Capoun O.; Comp\u00e9rat E.M.; Escrig D.J.L.; Andersson G.I.; Liedberg F.; Mariappan P.; Mostafid H.A.; Pradere B.; Rhijn V.B.W.G.; Shariat S.F.; Rai B.P.; Soria F.; Soukup V.; Wood R.G.; Xylinas E.N.; Lecomte M.A.; Gontero P.; European association of urology guidelines on upper urinary tract urothelial carcinoma: 2023 update. Eur Urol  2023,84(1),49-64","journal-title":"Eur Urol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1111\/j.1464-410X.2010.09675.x","volume":"107","author":"Raman J.D.","year":"2011","unstructured":"Raman J.D.; Messer J.; Sielatycki J.A.; Hollenbeak C.S.; Incidence and survival of patients with carcinoma of the ureter and renal pelvis in the USA, 1973\u20132005. BJU Int  2011,107(7),1059-1064","journal-title":"BJU Int"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/ncpuro0875","volume":"4","author":"Raman J.D.","year":"2007","unstructured":"Raman J.D.; Scherr D.S.; Management of patients with upper urinary tract transitional cell carcinoma. Nat Clin Pract Urol  2007,4(8),432-443","journal-title":"Nat Clin Pract Urol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1097\/MOU.0000000000001078","volume":"33","author":"Krajewski W.","year":"2023","unstructured":"Krajewski W.; \u0141aszkiewicz J.; Nowak \u0141.; Szyde\u0142ko T.; Current methods facilitating diagnosis of upper tract urothelial carcinoma: A comprehensive literature review. Curr Opin Urol  2023,33(3),230-238","journal-title":"Curr Opin Urol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"e0144961","DOI":"10.1371\/journal.pone.0144961","volume":"10","author":"Zhang B.","year":"2015","unstructured":"Zhang B.; Yu W.; Zhou L.Q.; He Z.S.; Shen C.; He Q.; Li J.; Liu L.B.; Wang C.; Chen X.Y.; Fan Y.; Hu S.; Zhang L.; Han W.K.; Jin J.; Prognostic significance of preoperative albumin-globulin ratio in patients with upper tract urothelial carcinoma. PLoS One  2015,10(12),e0144961","journal-title":"PLoS One"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1158\/0008-5472.CAN-10-2583","volume":"71","author":"Gregory A.D.","year":"2011","unstructured":"Gregory A.D.; Houghton M.A.; Tumor-associated neutrophils: New targets for cancer therapy. Cancer Res  2011,71(7),2411-2416","journal-title":"Cancer Res"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"4041","DOI":"10.1245\/s10434-014-3830-3","volume":"21","author":"Tanaka N.","year":"2014","unstructured":"Tanaka N.; Kikuchi E.; Kanao K.; Matsumoto K.; Shirotake S.; Miyazaki Y.; Kobayashi H.; Kaneko G.; Hagiwara M.; Ide H.; Obata J.; Hoshino K.; Hayakawa N.; Kosaka T.; Hara S.; Oyama M.; Momma T.; Nakajima Y.; Jinzaki M.; Oya M.; A multi-institutional validation of the prognostic value of the neutrophil-to-lymphocyte ratio for upper tract urothelial carcinoma treated with radical nephroureterectomy. Ann Surg Oncol  2014,21(12),4041-4048","journal-title":"Ann Surg Oncol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"5241","DOI":"10.3892\/ol.2019.10178","volume":"17","author":"Nishihara K.","year":"2019","unstructured":"Nishihara K.; Suekane S.; Ueda K.; Nakiri M.; Matsuo M.; Igawa T.; High postoperative neutrophil-to-lymphocyte ratio as a poor prognostic marker in patients with upper tract urothelial carcinoma. Oncol Lett  2019,17(6),5241-5250","journal-title":"Oncol Lett"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s10147-016-1040-7","volume":"22","author":"Kishimoto N.","year":"2017","unstructured":"Kishimoto N.; Takao T.; Kuribayashi S.; Yamamichi G.; Nakano K.; Kawamura M.; Tsutahara K.; Tanigawa G.; Yamaguchi S.; The neutrophil-to-lymphocyte ratio as a predictor of intravesical recurrence in patients with upper urinary tract urothelial carcinoma treated with radical nephroureterectomy. Int J Clin Oncol  2017,22(1),153-158","journal-title":"Int J Clin Oncol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1111\/bju.12846","volume":"115","author":"Sung H.H.","year":"2015","unstructured":"Sung H.H.; Jeon G.H.; Jeong B.C.; Seo S.I.; Jeon S.S.; Choi H.Y.; Lee H.M.; Clinical significance of prognosis using the neutrophil\u2013lymphocyte ratio and erythrocyte sedimentation rate in patients undergoing radical nephroureterectomy for upper urinary tract urothelial carcinoma. BJU Int  2015,115(4),587-594","journal-title":"BJU Int"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"9023","DOI":"10.2147\/CMAR.S274332","volume":"12","author":"Zhao Z.","year":"2020","unstructured":"Zhao Z.; Xie S.; Feng B.; Zhang S.; Sun Y.; Guo H.; Yang R.; Preoperative risk classification using neutrophil-to-lymphocyte ratio and albumin for upper tract urothelial carcinoma treated with radical nephroureterectomy. Cancer Manag Res  2020,12,9023-9032","journal-title":"Cancer Manag Res"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"e484","DOI":"10.1016\/j.clgc.2019.12.008","volume":"18","author":"Jan H.C.","year":"2020","unstructured":"Jan H.C.; Hu C.Y.; Yang W.H.; Ou C.H.; Combination of platelet-lymphocyte ratio and monocyte-lymphocyte ratio as a new promising prognostic factor in upper tract urothelial carcinoma with large tumor sizes > 3 cm. Clin Genitourin Cancer  2020,18(4),e484-e500","journal-title":"Clin Genitourin Cancer"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"300","DOI":"10.23736\/S0393-2249.18.02914-4","volume":"70","author":"Son S.","year":"2018","unstructured":"Son S.; Hwang E.C.; Jung S.I.; Kwon D.D.; Choi S.H.; Kwon T.G.; Noh J.H.; Kim M.K.; Seo I.Y.; Kim C.S.; Kang S.G.; Cheon J.; Ha H.K.; Jeong C.W.; Ku J.H.; Kwak C.; Kim H.H.; Prognostic value of preoperative systemic inflammation markers in localized upper tract urothelial cell carcinoma: A large, multicenter cohort analysis. Minerva Urol Nephrol  2018,70(3),300-309","journal-title":"Minerva Urol Nephrol"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1084\/jem.52.4.561","volume":"52","author":"Tillett W.S.","year":"1930","unstructured":"Tillett W.S.; Francis T.; Serological reactions in pneumonia with a non-protein somatic fraction of pneumococcus. J Exp Med  1930,52(4),561-571","journal-title":"J Exp Med"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1007\/s11912-002-0023-1","volume":"4","author":"Mahmoud F.A.","year":"2002","unstructured":"Mahmoud F.A.; Rivera N.I.; The role of C-reactive protein as a prognostic indicator in advanced cancer. Curr Oncol Rep  2002,4(3),250-255","journal-title":"Curr Oncol Rep"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1016\/j.urolonc.2012.05.008","volume":"31","author":"Obata J.","year":"2013","unstructured":"Obata J.; Kikuchi E.; Tanaka N.; Matsumoto K.; Hayakawa N.; Ide H.; Miyajima A.; Nakagawa K.; Oya M.; C-reactive protein: A biomarker of survival in patients with localized upper tract urothelial carcinoma treated with radical nephroureterectomy. Urol Oncol  2013,31(8),1725-1730","journal-title":"Urol Oncol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1159\/000362248","volume":"93","author":"Aziz A.","year":"2014","unstructured":"Aziz A.; Rink M.; Gakis G.; Kluth L.A.; Dechet C.; Miller F.; Otto W.; Gierth M.; Denzinger S.; Schwentner C.; Stenzl A.; Fisch M.; Burger M.; Fritsche H.M.; Preoperative C-reactive protein in the serum: A prognostic biomarker for upper urinary tract urothelial carcinoma treated with radical nephroureterectomy. Urol Int  2014,93(3),352-360","journal-title":"Urol Int"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/1471-2407-13-101","volume":"13","author":"Stein B.","year":"2013","unstructured":"Stein B.; Schrader A.J.; Wegener G.; Seidel C.; Kuczyk M.A.; Steffens S.; Preoperative serum C- reactive protein: A prognostic marker in patients with upper urinary tract urothelial carcinoma. BMC Cancer  2013,13(1),101","journal-title":"BMC Cancer"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1007\/s00345-023-04379-y","volume":"41","author":"Egger V.","year":"2023","unstructured":"Egger V.; Hutterer G.C.; Mischinger J.; Seles M.; Pichler R.; Mannweiler S.; Huber K.; Balihodzic A.; Spiegelberg J.; Bauernhofer T.; Ahyai S.; Zigeuner R.; Pichler M.; Barth D.A.; Preoperative fibrinogen\/CRP score predicts survival in upper urothelial tract carcinoma patients undergoing radical curative surgery. World J Urol  2023,41(5),1359-1364","journal-title":"World J Urol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.euf.2015.02.001","volume":"1","author":"Tanaka N.","year":"2015","unstructured":"Tanaka N.; Kikuchi E.; Kanao K.; Matsumoto K.; Shirotake S.; Miyazaki Y.; Kobayashi H.; Kaneko G.; Hagiwara M.; Ide H.; Obata J.; Hoshino K.; Hayakawa N.; Kosaka T.; Hara S.; Nakagawa K.; Jinzaki M.; Oya M.; Impact of combined use of blood-based inflammatory markers on patients with upper tract urothelial carcinoma following radical nephroureterectomy: Proposal of a cumulative marker score as a novel predictive tool for prognosis. Eur Urol Focus  2015,1(1),54-63","journal-title":"Eur Urol Focus"},{"key":"ref=23","first-page":"4719","volume":"60","author":"Wilbraham B.C.A.","year":"2000","unstructured":"Wilbraham B.C.A.; Tazzyman S.; Marshall J.M.; Lewis C.E.; Fibrinogen E-fragment inhibits the migration and tubule formation of human dermal microvascular endothelial cells in vitro. Cancer Res  2000,60(17),4719-4724","journal-title":"Cancer Res"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1159\/000012167","volume":"59","author":"Lee S.Y.","year":"2000","unstructured":"Lee S.Y.; Park L.O.; Suk S.H.; Role of fibrinogen covalently associated with cell membrane in blood-borne lung tumor colony formation of murine mammary carcinoma cells. Oncology  2000,59(3),238-244","journal-title":"Oncology"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.ijsu.2019.03.022","volume":"65","author":"Liu R.","year":"2019","unstructured":"Liu R.; Zhou X.; Zou L.; Chen Q.; Hu Y.; Hu J.; Wu X.; Jiang H.; Clinicopathological and prognostic significance of preoperative plasma fibrinogen level in patients with upper urinary tract urothelial carcinoma: A retrospective tumor marker prognostic study. Int J Surg  2019,65,88-93","journal-title":"Int J Surg"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1245\/s10434-015-4781-z","volume":"23","author":"Cheng Y.C.","year":"2016","unstructured":"Cheng Y.C.; Huang C.N.; Wu W.J.; Li C.C.; Ke H.L.; Li W.M.; Tu H.P.; Li C.F.; Chang L.L.; Yeh H.C.; The prognostic significance of inflammation-associated blood cell markers in patients with upper tract urothelial carcinoma. Ann Surg Oncol  2016,23(1),343-351","journal-title":"Ann Surg Oncol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"e1059","DOI":"10.1016\/j.clgc.2018.06.003","volume":"16","author":"Xu H.","year":"2018","unstructured":"Xu H.; Tan P.; Ai J.; Huang Y.; Lin T.; Yang L.; Wei Q.; Prognostic impact of preoperative albumin\u2013globulin ratio on oncologic outcomes in upper tract urothelial carcinoma treated with radical nephroureterectomy. Clin Genitourin Cancer  2018,16(5),e1059-e1068","journal-title":"Clin Genitourin Cancer"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"36772","DOI":"10.18632\/oncotarget.13694","volume":"8","author":"Huang J.","year":"2017","unstructured":"Huang J.; Wang Y.; Yuan Y.; Chen Y.; Kong W.; Chen H.; Zhang J.; Huang Y.; Preoperative serum pre-albumin as an independent prognostic indicator in patients with localized upper tract urothelial carcinoma after radical nephroureterectomy. Oncotarget  2017,8(22),36772-36779","journal-title":"Oncotarget"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"12311","DOI":"10.1038\/s41598-018-29833-5","volume":"8","author":"Tan P.","year":"2018","unstructured":"Tan P.; Xie N.; Ai J.; Xu H.; Xu H.; Liu L.; Yang L.; Wei Q.; The prognostic significance of Albumin-to-Alkaline Phosphatase Ratio in upper tract urothelial carcinoma. Sci Rep  2018,8(1),12311","journal-title":"Sci Rep"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"672","DOI":"10.3390\/biomedicines9060672","volume":"9","author":"Su Y.C.","year":"2021","unstructured":"Su Y.C.; Wen S.C.; Li C.C.; Su H.C.; Ke H.L.; Li W.M.; Lee H.Y.; Li C.Y.; Yang S.F.; Tu H.P.; Wu W.J.; Yeh H.C.; Low hemoglobin-to-red cell distribution width ratio is associated with disease progression and poor prognosis in upper tract urothelial carcinoma. Biomedicines  2021,9(6),672","journal-title":"Biomedicines"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"731318","DOI":"10.3389\/fonc.2021.731318","volume":"11","author":"Fan B.","year":"2021","unstructured":"Fan B.; Huang Y.; Wen S.; Teng Q.; Yang X.; Sun M.; Chen T.; Huang Y.; Wang Y.; Liu Z.; Predictive value of preoperative positive urine cytology for development of bladder cancer after nephroureterectomy in patients with upper urinary tract urothelial carcinoma: A prognostic nomogram based on a retrospective multicenter cohort study and systematic meta-analysis. Front Oncol  2021,11,731318","journal-title":"Front Oncol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1081\/JDI-100104725","volume":"23","author":"Bianchi C.","year":"2001","unstructured":"Bianchi C.; Donadio C.; Tramonti G.; Consani C.; Lorusso P.; Rossi G.; Reappraisal of serum \u03b22-microglobulin as marker of GFR. Ren Fail  2001,23(3-4),419-429","journal-title":"Ren Fail"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"323","DOI":"10.5980\/jpnjurol1928.68.4_323","volume":"68","author":"Yokoyama E","year":"1977","unstructured":"Yokoyama E; Furuya S; Kumamoto Y.; Clinical evaluation on quantitation of serum and urinary beta2-microglobulin, especially as an index of renal tubular function (author's transl). Nihon Hinyokika Gakkai Zasshi  1977,68(4),323-36","journal-title":"Nihon Hinyokika Gakkai Zasshi"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"1008763","DOI":"10.3389\/fonc.2022.1008763","volume":"12","author":"Han J.H.","year":"2022","unstructured":"Han J.H.; Jeong S.; Kim S.H.; Yuk H.D.; Jeong C.W.; Kwak C.; Ku J.H.; Increased urinary B2-microglobulin is associated with poor prognosis of upper tract urothelial carcinoma. Front Oncol  2022,12,1008763","journal-title":"Front Oncol"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1245\/s10434-016-5555-y","volume":"23","author":"Ide H.","year":"2016","unstructured":"Ide H.; Kikuchi E.; Hagiwara M.; Hayakawa N.; Hongo H.; Miyajima A.; Oya M.; Urinary pH levels are strongly associated with bladder recurrence after nephroureterectomy in upper tract urothelial carcinoma patients with a smoking history. Ann Surg Oncol  2016,23(S5),1029-1038","journal-title":"Ann Surg Oncol"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"817781","DOI":"10.3389\/fonc.2021.817781","volume":"11","author":"Han J.H.","year":"2022","unstructured":"Han J.H.; Jeong S.; Yuk H.D.; Jeong C.W.; Kwak C.; Ku J.H.; Acidic urine is associated with poor prognosis of upper tract urothelial carcinoma. Front Oncol  2022,11,817781","journal-title":"Front Oncol"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"5423","DOI":"10.3390\/cancers14215423","volume":"14","author":"Ke C.","year":"2022","unstructured":"Ke C.; Hu Z.; Yang C.; UroVysion fluorescence in situ hybridization in urological cancers: A narrative review and future perspectives. Cancers  2022,14(21),5423","journal-title":"Cancers"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"14652","DOI":"10.18632\/oncotarget.24007","volume":"9","author":"Guan B.","year":"2018","unstructured":"Guan B.; Du Y.; Su X.; Cao Z.; Li Y.; Zhan Y.; Peng D.; Xiong G.; Fang D.; Ding Y.; He S.; Gong Y.; He Q.; Li X.; Zhou L.; Positive urinary fluorescence in situ hybridization indicates poor prognosis in patients with upper tract urothelial carcinoma. Oncotarget  2018,9(18),14652-14660","journal-title":"Oncotarget"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1111\/j.1742-4658.2006.05135.x","volume":"273","author":"Clement P.M.J.","year":"2006","unstructured":"Clement P.M.J.; Johansson H.E.; Wolff E.C.; Park M.H.; Differential expression of eIF5A-1 and eIF5A-2 in human cancer cells. FEBS J  2006,273(6),1102-1114","journal-title":"FEBS J"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1158\/1055-9965.EPI-08-0754","volume":"18","author":"Chen W.","year":"2009","unstructured":"Chen W.; Luo J.H.; Hua W.F.; Zhou F.J.; Lin M.C.; Kung H.F.; Zeng Y.X.; Guan X.Y.; Xie D.; Overexpression of EIF-5A2 is an independent predictor of outcome in patients of urothelial carcinoma of the bladder treated with radical cystectomy. Cancer Epidemiol Biomarkers Prev  2009,18(2),400-408","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1111\/j.1349-7006.2009.01126.x","volume":"100","author":"Luo J.H.","year":"2009","unstructured":"Luo J.H.; Hua W.F.; Rao H.L.; Liao Y.J.; Kung H.F.; Zeng Y.X.; Guan X.Y.; Chen W.; Xie D.; Overexpression of EIF-5A2 predicts tumor recurrence and progression in pTa\/pT1 urothelial carcinoma of the bladder. Cancer Sci  2009,100(5),896-902","journal-title":"Cancer Sci"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1038\/bjc.2014.52","volume":"110","author":"Wei J-H.","year":"2014","unstructured":"Wei J-H.; Cao J-Z.; Zhang D.; Liao B.; Zhong W-M.; Lu J.; Zhao H-W.; Zhang J-X.; Tong Z-T.; Fan S.; Liang C-Z.; Liao Y-B.; Pang J.; Wu R-H.; Fang Y.; Chen Z-H.; Li B.; Xie D.; Chen W.; Luo J-H.; EIF5A2 predicts outcome in localised invasive bladder cancer and promotes bladder cancer cell aggressiveness in vitro and in vivo. Br J Cancer  2014,110(7),1767-1777","journal-title":"Br J Cancer"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.2217\/fon-2018-0748","volume":"15","author":"Fang Y.","year":"2019","unstructured":"Fang Y.; Cen J.J.; Cao J.Z.; Huang Y.; Feng Z.H.; Lu J.; Wei J.H.; Chen Z.H.; Liang Y.P.; Liao B.; Luo J.H.; Chen W.; Overexpression of EIF5A2 in upper urinary tract urothelial carcinoma is a new independent prognostic marker of survival. Future Oncol  2019,15(17),2009-2018","journal-title":"Future Oncol"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"6997","DOI":"10.2147\/CMAR.S185392","volume":"10","author":"Huang Y.","year":"2018","unstructured":"Huang Y.; Wei J.; Fang Y.; Chen Z.; Cen J.; Feng Z.; Lu J.; Liang Y.; Luo J.; Chen W.; Prognostic value of AIB1 and EIF5A2 in intravesical recurrence after surgery for upper tract urothelial carcinoma. Cancer Manag Res  2018,10,6997-7011","journal-title":"Cancer Manag Res"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"151","DOI":"10.3233\/CBM-182020","volume":"25","author":"Huang Y.","year":"2019","unstructured":"Huang Y.; Cen J.; Wei J.; Chen Z.; Fang Y.; Feng Z.; Lu J.; Liang Y.; Luo J.; Mo C.; Chen W.; Impact of AIB1 expression on the prognosis of upper tract urothelial carcinoma after radical nephroureterectomy. Cancer Biomark  2019,25(2),151-160","journal-title":"Cancer Biomark"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"10846","DOI":"10.3390\/ijms241310846","volume":"24","author":"Aveta A.","year":"2023","unstructured":"Aveta A.; Cilio S.; Contieri R.; Spena G.; Napolitano L.; Manfredi C.; Franco A.; Crocerossa F.; Cerrato C.; Ferro M.; Giudice D.F.; Verze P.; Lasorsa F.; Salonia A.; Nair R.; Walz J.; Lucarelli G.; Pandolfo S.D.; Urinary microRNAs as biomarkers of urological cancers: A systematic review. Int J Mol Sci  2023,24(13),10846","journal-title":"Int J Mol Sci"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1111\/bju.12551","volume":"113","author":"Izquierdo L.","year":"2014","unstructured":"Izquierdo L.; Torres I.M.; Mallofr\u00e9 C.; Lozano J.J.; Crinquette V.M.; Leroy X.; Colin P.; Comperat E.; Roupret M.; Alcaraz A.; Mengual L.; Prognostic value of microRNA expression pattern in upper tract urothelial carcinoma. BJU Int  2014,113(5),813-821","journal-title":"BJU Int"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"51522","DOI":"10.18632\/oncotarget.17884","volume":"8","author":"Izquierdo L.","year":"2017","unstructured":"Izquierdo L.; Montalbo R.; Torres I.M.; Mallofr\u00e9 C.; Backhaus R.M.; Rubio J.; Van der Heijden A.G.; Schaafsma E.; Beltran L.A.; Blanca A.; Lawrentschuk N.; Alcaraz A.; Mengual L.; Prognostic microRNAs in upper tract urothelial carcinoma: Multicenter and international validation study. Oncotarget  2017,8(31),51522-51529","journal-title":"Oncotarget"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1038\/ng.2702","volume":"45","author":"Roberts S.A.","year":"2013","unstructured":"Roberts S.A.; Lawrence M.S.; Klimczak L.J.; Grimm S.A.; Fargo D.; Stojanov P.; Kiezun A.; Kryukov G.V.; Carter S.L.; Saksena G.; Harris S.; Shah R.R.; Resnick M.A.; Getz G.; Gordenin D.A.; An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat Genet  2013,45(9),970-976","journal-title":"Nat Genet"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1038\/ng.3670","volume":"48","author":"Middlebrooks C.D.","year":"2016","unstructured":"Middlebrooks C.D.; Banday A.R.; Matsuda K.; Udquim K.I.; Onabajo O.O.; Paquin A.; Figueroa J.D.; Zhu B.; Koutros S.; Kubo M.; Shuin T.; Freedman N.D.; Kogevinas M.; Malats N.; Chanock S.J.; Closas G.M.; Silverman D.T.; Rothman N.; Olsson P.L.; Association of germline variants in the APOBEC3 region with cancer risk and enrichment with APOBEC-signature mutations in tumors. Nat Genet  2016,48(11),1330-1338","journal-title":"Nat Genet"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"10002","DOI":"10.1073\/pnas.170093297","volume":"97","author":"Duensing S.","year":"2000","unstructured":"Duensing S.; Lee L.Y.; Duensing A.; Basile J.; Piboonniyom S.; Gonzalez S.; Crum C.P.; M\u00fcnger K.; The human papillomavirus type 16 E6 and E7 oncoproteins cooperate to induce mitotic defects and genomic instability by uncoupling centrosome duplication from the cell division cycle. Proc Natl Acad Sci  2000,97(18),10002-10007","journal-title":"Proc Natl Acad Sci"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1016\/j.cell.2019.02.012","volume":"176","author":"Petljak M.","year":"2019","unstructured":"Petljak M.; Alexandrov L.B.; Brammeld J.S.; Price S.; Wedge D.C.; Grossmann S.; Dawson K.J.; Ju Y.S.; Iorio F.; Tubio J.M.C.; Koh C.C.; Soares G.I.; Mart\u00edn R.B.; Otlu B.; O\u2019Meara S.; Butler A.P.; Menzies A.; Bhosle S.G.; Raine K.; Jones D.R.; Teague J.W.; Beal K.; Latimer C.; O\u2019Neill L.; Zamora J.; Anderson E.; Patel N.; Maddison M.; Ng B.L.; Graham J.; Garnett M.J.; McDermott U.; Zainal N.S.; Campbell P.J.; Stratton M.R.; Characterizing mutational signatures in human cancer cell lines reveals episodic APOBEC mutagenesis. Cell  2019,176(6),1282-1294.e20","journal-title":"Cell"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.eururo.2017.05.048","volume":"72","author":"Moss T.J.","year":"2017","unstructured":"Moss T.J.; Qi Y.; Xi L.; Peng B.; Kim T.B.; Ezzedine N.E.; Mosqueda M.E.; Guo C.C.; Czerniak B.A.; Ittmann M.; Wheeler D.A.; Lerner S.P.; Matin S.F.; Comprehensive genomic characterization of upper tract urothelial carcinoma. Eur Urol  2017,72(4),641-649","journal-title":"Eur Urol"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2022\/2147494","volume":"2022","author":"He L.","year":"2022","unstructured":"He L.; Yang B.; Jian D.; Luo H.; Wang D.; Dai N.; Prognostic value of HPV E6 and APOBEC3B in upper urinary tract urothelial carcinoma. Dis Markers  2022,2022,1-9","journal-title":"Dis Markers"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"8969","DOI":"10.1128\/MCB.20.23.8969-8982.2000","volume":"20","author":"Nakamura N.","year":"2000","unstructured":"Nakamura N.; Ramaswamy S.; Vazquez F.; Signoretti S.; Loda M.; Sellers W.R.; Forkhead transcription factors are critical effectors of cell death and cell cycle arrest downstream of PTEN. Mol Cell Biol  2000,20(23),8969-8982","journal-title":"Mol Cell Biol"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1007\/s00018-015-2112-y","volume":"73","author":"de Brach\u00e8ne C.A.","year":"2016","unstructured":"de Brach\u00e8ne C.A.; Demoulin J.B.; FOXO transcription factors in cancer development and therapy. Cell Mol Life Sci  2016,73(6),1159-1172","journal-title":"Cell Mol Life Sci"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"14","DOI":"10.2174\/156800912798888965","volume":"12","author":"Miyamoto H.","year":"2012","unstructured":"Miyamoto H.; Zheng Y.; Izumi K.; Nuclear hormone receptor signals as new therapeutic targets for urothelial carcinoma. Curr Canc Drug Targ  2012,12(1),14-22","journal-title":"Curr Canc Drug Targ"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/nrurol.2013.53","volume":"10","author":"Hsu I.","year":"2013","unstructured":"Hsu I.; Vitkus S.; Da J.; Yeh S.; Role of oestrogen receptors in bladder cancer development. Nat Rev Urol  2013,10(6),317-326","journal-title":"Nat Rev Urol"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.mce.2017.06.021","volume":"465","author":"Inoue S.","year":"2018","unstructured":"Inoue S.; Mizushima T.; Miyamoto H.; Role of the androgen receptor in urothelial cancer. Mol Cell Endocrinol  2018,465,73-81","journal-title":"Mol Cell Endocrinol"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"482","DOI":"10.3892\/ol.2018.9510","volume":"17","author":"Ide H.","year":"2018","unstructured":"Ide H.; Jiang G.; Mizushima T.; Fujita K.; Inoue S.; Yamaguchi S.; Fushimi H.; Nonomura N.; Miyamoto H.; Forkhead box O1 as an indicator of prognosis is inactivated in urothelial carcinoma of the upper urinary tract. Oncol Lett  2018,17(1),482-487","journal-title":"Oncol Lett"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"154","DOI":"10.3390\/cancers10060154","volume":"10","author":"Kanapathipillai M.","year":"2018","unstructured":"Kanapathipillai M.; Treating p53 mutant aggregation-associated cancer. Cancers  2018,10(6),154","journal-title":"Cancers"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1159\/000360227","volume":"94","author":"Lee J.Y.","year":"2015","unstructured":"Lee J.Y.; Cho K.S.; Diaz R.R.; Choi Y.D.; Choi H.Y.; p53 expression as a prognostic factor in upper urinary tract urothelial carcinoma: A systematic review and meta-analysis. Urol Int  2015,94(1),50-57","journal-title":"Urol Int"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1016\/j.juro.2014.11.007","volume":"193","author":"Krabbe L.M.","year":"2015","unstructured":"Krabbe L.M.; Bagrodia A.; Haddad A.Q.; Kapur P.; Khalil D.; Hynan L.S.; Wood C.G.; Karam J.A.; Weizer A.Z.; Raman J.D.; Remzi M.; Leclercq R.N.; Haitel A.; Roscigno M.; Bolenz C.; Bensalah K.; Sagalowsky A.I.; Shariat S.F.; Lotan Y.; Margulis V.; Multi-institutional validation of the predictive value of Ki-67 in patients with high grade urothelial carcinoma of the upper urinary tract. J Urol  2015,193(5),1486-1493","journal-title":"J Urol"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1007\/s00262-021-02890-y","volume":"70","author":"Chen C.H.","year":"2021","unstructured":"Chen C.H.; Tsai M.Y.; Chiang P.C.; Sung M.T.; Luo H.L.; Suen J.L.; Tsai E.M.; Chiang P.H.; Prognostic value of PD-L1 combined positive score in patients with upper tract urothelial carcinoma. Cancer Immunol Immunother  2021,70(10),2981-2990","journal-title":"Cancer Immunol Immunother"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1186\/s12885-022-09893-7","volume":"22","author":"Miyai K.","year":"2022","unstructured":"Miyai K.; Kawamura K.; Ito K.; Matsukuma S.; Tsuda H.; Prognostic impact of stromal periostin expression in upper urinary tract urothelial carcinoma. BMC Cancer  2022,22(1),787","journal-title":"BMC Cancer"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1111\/j.1349-7006.2010.01506.x","volume":"101","author":"Szarvas T.","year":"2010","unstructured":"Szarvas T.; Becker M.; Dorp V.F.; Gethmann C.; T\u00f6tsch M.; B\u00e1nkfalvi \u00c1.; Schmid K.W.; Romics I.; R\u00fcbben H.; Erg\u00fcn S.; Matrix metalloproteinase-7 as a marker of metastasis and predictor of poor survival in bladder cancer. Cancer Sci  2010,101(5),1300-1308","journal-title":"Cancer Sci"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"698","DOI":"10.3390\/biomedicines10030698","volume":"10","author":"Kov\u00e1cs P.T.","year":"2022","unstructured":"Kov\u00e1cs P.T.; Mayer T.; Csizmarik A.; V\u00e1radi M.; Ol\u00e1h C.; Sz\u00e9les \u00c1.; Tschirdewahn S.; Krafft U.; Hadaschik B.; Nyir\u00e1dy P.; Riesz P.; Szarvas T.; Elevated pre-treatment serum MMP-7 levels are associated with the presence of metastasis and poor survival in upper tract urothelial carcinoma. Biomedicines  2022,10(3),698","journal-title":"Biomedicines"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1359\/jbmr.2002.17.8.1486","volume":"17","author":"Suzuki K.","year":"2002","unstructured":"Suzuki K.; Zhu B.; Rittling S.R.; Denhardt D.T.; Goldberg H.A.; Mcculloch C.A.G.; Sodek J.; Colocalization of intracellular osteopontin with CD44 is associated with migration, cell fusion, and resorption in osteoclasts. J Bone Miner Res  2002,17(8),1486-1497","journal-title":"J Bone Miner Res"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.urolonc.2009.10.009","volume":"29","author":"Ke H.L.","year":"2011","unstructured":"Ke H.L.; Chang L.L.; Yang S.F.; Lin H.H.; Li C.C.; Wu D.C.; Wu W.J.; Osteopontin overexpression predicts poor prognosis of upper urinary tract urothelial carcinoma. Urol Oncol  2011,29(6),703-709","journal-title":"Urol Oncol"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"108744","DOI":"10.1016\/j.biopha.2019.108744","volume":"113","author":"Li Y.","year":"2019","unstructured":"Li Y.; He S.; He A.; Guan B.; Ge G.; Zhan Y.; Wu Y.; Gong Y.; Peng D.; Bao Z.; Li X.; Zhou L.; Identification of plasma secreted phosphoprotein 1 as a novel biomarker for upper tract urothelial carcinomas. Biomed Pharmacother  2019,113,108744","journal-title":"Biomed Pharmacother"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1083\/jcb.140.6.1383","volume":"140","author":"Honda K.","year":"1998","unstructured":"Honda K.; Yamada T.; Endo R.; Ino Y.; Gotoh M.; Tsuda H.; Yamada Y.; Chiba H.; Hirohashi S.; Actinin-4, a novel actin-bundling protein associated with cell motility and cancer invasion. J Cell Biol  1998,140(6),1383-1393","journal-title":"J Cell Biol"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1272\/jnms.JNMS.2022_89-118","volume":"89","author":"Honda K.","year":"2022","unstructured":"Honda K.; Development of biomarkers to predict recurrence by determining the metastatic ability of cancer cells. J Nippon Med Sch  2022,89(1),24-32","journal-title":"J Nippon Med Sch"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3390\/jcm5050051","volume":"5","author":"Grigore A.","year":"2016","unstructured":"Grigore A.; Jolly M.; Jia D.; Carson F.M.; Levine H.; Tumor budding: The name is EMT. Partial EMT. J Clin Med  2016,5(5),51","journal-title":"J Clin Med"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.3390\/cells8111427","volume":"8","author":"Tentler D.","year":"2019","unstructured":"Tentler D.; Lomert E.; Novitskaya K.; Barlev N.A.; Role of ACTN4 in tumorigenesis, metastasis, and EMT. Cells  2019,8(11),1427","journal-title":"Cells"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1053\/j.gastro.2004.10.004","volume":"128","author":"Honda K.","year":"2005","unstructured":"Honda K.; Yamada T.; Hayashida Y.; Idogawa M.; Sato S.; Hasegawa F.; Ino Y.; Ono M.; Hirohashi S.; Actinin-4 increases cell motility and promotes lymph node metastasis of colorectal cancer. Gastroenterology  2005,128(1),51-62","journal-title":"Gastroenterology"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"e0120616","DOI":"10.1371\/journal.pone.0120616","volume":"10","author":"Fukumoto M.","year":"2015","unstructured":"Fukumoto M.; Kurisu S.; Yamada T.; Takenawa T.; \u03b1-Actinin-4 enhances colorectal cancer cell invasion by suppressing focal adhesion maturation. PLoS One  2015,10(4),e0120616","journal-title":"PLoS One"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.bbapap.2017.02.012","volume":"1865","author":"Proch\u00e1zkov\u00e1 I.","year":"2017","unstructured":"Proch\u00e1zkov\u00e1 I.; Len\u010do J.; Fu\u010d\u00edkov\u00e1 A.; Dresler J.; \u010c\u00e1pkov\u00e1 L.; Hrstka R.; Nenutil R.; Bouchal P.; Targeted proteomics driven verification of biomarker candidates associated with breast cancer aggressiveness. Biochim Biophys Acta Proteins Proteomics  2017,1865(5),488-498","journal-title":"Biochim Biophys Acta Proteins Proteomics"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"3298","DOI":"10.12659\/MSM.912404","volume":"25","author":"Fang C.","year":"2019","unstructured":"Fang C.; Li J.J.; Deng T.; Li B.H.; Geng P.L.; Zeng X.T.; Actinin-4 as a diagnostic biomarker in serum of breast cancer patients. Med Sci Monit  2019,25,3298-3302","journal-title":"Med Sci Monit"},{"key":"ref=79","first-page":"4695","volume":"9","author":"Yamagata N.","year":"2003","unstructured":"Yamagata N.; Shyr Y.; Yanagisawa K.; Edgerton M.; Dang T.P.; Gonzalez A.; Nadaf S.; Larsen P.; Roberts J.R.; Nesbitt J.C.; Jensen R.; Levy S.; Moore J.H.; Minna J.D.; Carbone D.P.; A training-testing approach to the molecular classification of resected non-small cell lung cancer. Clin Cancer Res  2003,9(13),4695-4704","journal-title":"Clin Cancer Res"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1097\/JTO.0000000000000396","volume":"10","author":"Wang M.C.","year":"2015","unstructured":"Wang M.C.; Chang Y.H.; Wu C.C.; Tyan Y.C.; Chang H.C.; Goan Y.G.; Lai W.W.; Cheng P.N.; Liao P.C.; Alpha-actinin 4 is associated with cancer cell motility and is a potential biomarker in non-small cell lung cancer. J Thorac Oncol  2015,10(2),286-301","journal-title":"J Thorac Oncol"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1093\/annonc\/mdt293","volume":"24","author":"Noro R.","year":"2013","unstructured":"Noro R.; Honda K.; Tsuta K.; Ishii G.; Maeshima A.M.; Miura N.; Furuta K.; Shibata T.; Tsuda H.; Ochiai A.; Sakuma T.; Nishijima N.; Gemma A.; Asamura H.; Nagai K.; Yamada T.; Distinct outcome of stage I lung adenocarcinoma with ACTN4 cell motility gene amplification. Ann Oncol  2013,24(10),2594-2600","journal-title":"Ann Oncol"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.jtho.2016.08.141","volume":"12","author":"Noro R.","year":"2017","unstructured":"Noro R.; Ishigame T.; Walsh N.; Shiraishi K.; Robles A.I.; Ryan B.M.; Schetter A.J.; Bowman E.D.; Welsh J.A.; Seike M.; Gemma A.; Skaug V.; Mollerup S.; Haugen A.; Yokota J.; Kohno T.; Harris C.C.; A two-gene prognostic classifier for early-stage lung squamous cell carcinoma in multiple large-scale and geographically diverse cohorts. J Thorac Oncol  2017,12(1),65-76","journal-title":"J Thorac Oncol"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"5348","DOI":"10.1158\/1078-0432.CCR-08-0075","volume":"14","author":"Kikuchi S.","year":"2008","unstructured":"Kikuchi S.; Honda K.; Tsuda H.; Hiraoka N.; Imoto I.; Kosuge T.; Umaki T.; Onozato K.; Shitashige M.; Yamaguchi U.; Ono M.; Tsuchida A.; Aoki T.; Inazawa J.; Hirohashi S.; Yamada T.; Expression and gene amplification of actinin-4 in invasive ductal carcinoma of the pancreas. Clin Cancer Res  2008,14(17),5348-5356","journal-title":"Clin Cancer Res"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.pan.2018.06.003","volume":"18","author":"Shoji H.","year":"2018","unstructured":"Shoji H.; Miura N.; Ueno H.; Honda K.; Measurement of copy number of ACTN4 to optimize the therapeutic strategy for locally advanced pancreatic cancer. Pancreatology  2018,18(6),624-629","journal-title":"Pancreatology"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1038\/modpathol.3800966","volume":"20","author":"Yamamoto S.","year":"2007","unstructured":"Yamamoto S.; Tsuda H.; Honda K.; Kita T.; Takano M.; Tamai S.; Inazawa J.; Yamada T.; Matsubara O.; Actinin-4 expression in ovarian cancer: A novel prognostic indicator independent of clinical stage and histological type. Mod Pathol  2007,20(12),1278-1285","journal-title":"Mod Pathol"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/modpathol.2008.234","volume":"22","author":"Yamamoto S.","year":"2009","unstructured":"Yamamoto S.; Tsuda H.; Honda K.; Onozato K.; Takano M.; Tamai S.; Imoto I.; Inazawa J.; Yamada T.; Matsubara O.; Actinin-4 gene amplification in ovarian cancer: A candidate oncogene associated with poor patient prognosis and tumor chemoresistance. Mod Pathol  2009,22(4),499-507","journal-title":"Mod Pathol"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1111\/j.1365-2559.2011.04163.x","volume":"60","author":"Yamamoto S.","year":"2012","unstructured":"Yamamoto S.; Tsuda H.; Honda K.; Takano M.; Tamai S.; Imoto I.; Inazawa J.; Yamada T.; Matsubara O.; ACTN4 gene amplification and actinin-4 protein overexpression drive tumour development and histological progression in a high-grade subset of ovarian clear-cell adenocarcinomas. Histopathology  2012,60(7),1073-1083","journal-title":"Histopathology"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1002\/cam4.214","volume":"3","author":"Watabe Y.","year":"2014","unstructured":"Watabe Y.; Mori T.; Yoshimoto S.; Nomura T.; Shibahara T.; Yamada T.; Honda K.; Copy number increase of ACTN4 is a prognostic indicator in salivary gland carcinoma. Cancer Med  2014,3(3),613-622","journal-title":"Cancer Med"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/j.ijom.2017.03.001","volume":"46","author":"Kakuya T.","year":"2017","unstructured":"Kakuya T.; Mori T.; Yoshimoto S.; Watabe Y.; Miura N.; Shoji H.; Onidani K.; Shibahara T.; Honda K.; Prognostic significance of gene amplification of ACTN4 in stage I and II oral tongue cancer. Int J Oral Maxillofac Surg  2017,46(8),968-976","journal-title":"Int J Oral Maxillofac Surg"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.bbrc.2019.12.084","volume":"523","author":"Ishizuya Y.","year":"2020","unstructured":"Ishizuya Y.; Uemura M.; Narumi R.; Tomiyama E.; Koh Y.; Matsushita M.; Nakano K.; Hayashi Y.; Wang C.; Kato T.; Hatano K.; Kawashima A.; Ujike T.; Fujita K.; Imamura R.; Adachi J.; Tomonaga T.; Nonomura N.; The role of actinin-4 (ACTN4) in exosomes as a potential novel therapeutic target in castration-resistant prostate cancer. Biochem Biophys Res Commun  2020,523(3),588-594","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.urology.2009.09.037","volume":"75","author":"Koizumi T.","year":"2010","unstructured":"Koizumi T.; Nakatsuji H.; Fukawa T.; Avirmed S.; Fukumori T.; Takahashi M.; Kanayama H.; The role of actinin-4 in bladder cancer invasion. Urology  2010,75(2),357-364","journal-title":"Urology"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.3892\/or.2013.2577","volume":"30","author":"Yoshii H.","year":"2013","unstructured":"Yoshii H.; Ito K.; Asano T.; Horiguchi A.; Hayakawa M.; Asano T.; Increased expression of \u03b1-actinin-4 is associated with unfavorable pathological features and invasiveness of bladder cancer. Oncol Rep  2013,30(3),1073-1080","journal-title":"Oncol Rep"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"3411","DOI":"10.1111\/cas.15841","volume":"114","author":"Kawamura K.","year":"2023","unstructured":"Kawamura K.; Miyai K.; Sato K.; Matsukuma S.; Honda K.; Ito K.; Tsuda H.; Copy number gain of ACTN4 is associated with poor prognosis in patients with upper urinary tract urothelial carcinoma. Cancer Sci  2023,114(8),3411-3422","journal-title":"Cancer Sci"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.7150\/jca.76977","volume":"14","author":"Kim H.S.","year":"2023","unstructured":"Kim H.S.; Lee H.S.; Ku J.H.; Prognostic impact of postoperative neutrophil-to-lymphocyte ratio on survival outcomes of patients treated with radical nephroureterectomy for upper urinary tract urothelial carcinoma: A single institution retrospective analysis using propensity score matching. J Cancer  2023,14(7),1174-1181","journal-title":"J Cancer"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"191","DOI":"10.4103\/iju.iju_22_24","volume":"40","author":"Ghorai R.P.","year":"2024","unstructured":"Ghorai R.P.; Nayak B.; Goel R.; Gupta P.; Raj R.; Kaushal S.; Nayyar R.; Kumar R.; Seth A.; The prognostic role of preoperative neutrophil-to-lymphocyte ratio in upper tract urothelial carcinoma. Indian J Urol  2024,40(3),191-196","journal-title":"Indian J Urol"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1093\/jjco\/hyae081","volume":"54","author":"Saito S.","year":"2024","unstructured":"Saito S.; Takahashi H.; Yata Y.; Takamizawa S.; Hara S.; Miyajima K.; Iwatani K.; Yasue K.; Nishikawa H.; Yamamoto T.; Koide H.; Sadakane I.; Atsuta M.; Mori K.; Imai Y.; Kayano S.; Murakami M.; Tashiro K.; Tsuzuki S.; Yamada H.; Miki J.; Urabe F.; Kimura T.; Associations between early changes in the neutrophil-to- lymphocyte ratio after radical nephroureterectomy and treatment outcomes. Jpn J Clin Oncol  2024,54(11),1201-1207","journal-title":"Jpn J Clin Oncol"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.4103\/0366-6999.213414","volume":"130","author":"Cao Z.P.","year":"2017","unstructured":"Cao Z.P.; Guan B.; Zhao G.Z.; Fang D.; Xiong G.Y.; Li X.S.; Zhou L.Q.; Validation of the pretreatment neutrophil-to-lymphocyte ratio as a prognostic factor in a large cohort of chinese patients with upper tract urothelial carcinoma. Chin Med J  2017,130(17),2063-2068","journal-title":"Chin Med J"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"2838","DOI":"10.21037\/tau-21-185","volume":"10","author":"Hashimoto M.","year":"2021","unstructured":"Hashimoto M.; Fujita K.; Nakayama T.; Fujimoto S.; Hamaguchi M.; Nishimoto M.; Kikuchi T.; Adomi S.; Banno E.; Velasco D.M.A.; Saito Y.; Shimizu N.; Mori Y.; Minami T.; Nozawa M.; Nose K.; Yoshimura K.; Uemura H.; Higher neutrophil-to-lymphocyte ratio after the first cycle of the first-line chemotherapy is associated with poor cancer specific survival of upper urinary tract carcinoma patients. Transl Androl Urol  2021,10(7),2838-2847","journal-title":"Transl Androl Urol"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"E84","DOI":"10.5489\/cuaj.8393","volume":"18","author":"Teishima J.","year":"2023","unstructured":"Teishima J.; Hirata J.; Toge T.; Uematsu R.; Mita Y.; Yoshii T.; Nakamura I.; Prognostic model using postoperative normalization of C-reactive protein levels in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy. Can Urol Assoc J  2023,18(3),E84-E90","journal-title":"Can Urol Assoc J"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"177","DOI":"10.4103\/aja.aja_38_19","volume":"22","author":"Yang L.","year":"2020","unstructured":"Yang L.; Wei Q.; Xu H.; Ai J-Z.; Tan P.; Lin T-H.; Jin X.; Gong L-N.; Lei H-R.; Pretreatment elevated fibrinogen level predicts worse oncologic outcomes in upper tract urothelial carcinoma. Asian J Androl  2020,22(2),177-183","journal-title":"Asian J Androl"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"102","DOI":"10.3892\/mco.2021.2264","volume":"14","author":"Kuroda K.","year":"2021","unstructured":"Kuroda K.; Tasaki S.; Asakuma J.; Horiguchi A.; Ito K.; Preoperative risk stratification using plasma fibrinogen levels can predict lymphovascular invasion and poor prognosis in patients with upper urinary tract urothelial carcinoma. Mol Clin Oncol  2021,14(5),102","journal-title":"Mol Clin Oncol"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1111\/iju.13767","volume":"25","author":"Otsuka M.","year":"2018","unstructured":"Otsuka M.; Kamasako T.; Uemura T.; Takeshita N.; Shinozaki T.; Kobayashi M.; Komaru A.; Fukasawa S.; Prognostic role of the preoperative serum albumin : Globulin ratio after radical nephroureterectomy for upper tract urothelial carcinoma. Int J Urol  2018,25(10),871-878","journal-title":"Int J Urol"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1590\/S1677-5538.IBJU.2014.06.06","volume":"40","author":"Ku J.H.","year":"2014","unstructured":"Ku J.H.; Kim M.; Choi W.S.; Kwak C.; Kim H.H.; Preoperative serum albumin as a prognostic factor in patients with upper urinary tract urothelial carcinoma. Int Braz J Urol  2014,40(6),753-762","journal-title":"Int Braz J Urol"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1007\/s10147-022-02216-7","volume":"27","author":"Aalami A.H.","year":"2022","unstructured":"Aalami A.H.; Aalami F.; Diagnostic performance of fluorescence in situ hybridization (FISH) in upper tract urothelial carcinoma (UTUC): A systematic review and meta-analysis. Int J Clin Oncol  2022,27(10),1605-1615","journal-title":"Int J Clin Oncol"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1159\/000513459","volume":"105","author":"Eismann L.","year":"2021","unstructured":"Eismann L.; Mumm J.N.; Bohn L.; W\u00fclfing C.; Clarke K.R.; Casuscelli J.; Waidelich R.; Stief C.G.; Schlenker B.; Rodler S.; The impact of fluorescence in situ hybridization on the staging of upper tract urothelial carcinoma. Urol Int  2021,105(7-8),631-636","journal-title":"Urol Int"},{"key":"ref=106","first-page":"8620","volume":"24","author":"Gomella L.G.","year":"2017","unstructured":"Gomella L.G.; Mann M.J.; Cleary R.C.; Hubosky S.G.; Bagley D.H.; Thumar A.B.; McCue P.A.; Lallas C.D.; Trabulsi E.J.; Fluorescence in situ hybridization (FISH) in the diagnosis of bladder and upper tract urothelial carcinoma: The largest single-institution experience to date. Can J Urol  2017,24(1),8620-8626","journal-title":"Can J Urol"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"26106","DOI":"10.18632\/oncotarget.15344","volume":"8","author":"Su X.","year":"2017","unstructured":"Su X.; Hao H.; Li X.; He Z.; Gong K.; Zhang C.; Cai L.; Zhang Q.; Yao L.; Ding Y.; Gong Y.; Fang D.; Zhang Z.; Zhou L.; Fluorescence in situ hybridization status of voided urine predicts invasive and high-grade upper tract urothelial carcinoma. Oncotarget  2017,8(16),26106-26111","journal-title":"Oncotarget"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"e13859","DOI":"10.1097\/MD.0000000000013859","volume":"97","author":"Jin H.","year":"2018","unstructured":"Jin H.; Lin T.; Hao J.; Qiu S.; Xu H.; Yu R.; Sun S.; Zhang P.; Liu Z.; Yang L.; Liu L.; Han P.; Wei Q.; A comprehensive comparison of fluorescence in situ hybridization and cytology for the detection of upper urinary tract urothelial carcinoma. Medicine  2018,97(52),e13859","journal-title":"Medicine"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"183","DOI":"10.3892\/ol.2016.4592","volume":"12","author":"Yu Q.","year":"2016","unstructured":"Yu Q.; Li Y.; Li G.; Li T.; Zeng H.; Yang Z.; Wang D.; Prospective evaluation of FISH for detecting upper tract urothelial carcinoma in voided urine specimens. Oncol Lett  2016,12(1),183-188","journal-title":"Oncol Lett"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"107","DOI":"10.22037\/uj.v20i.7973","volume":"21","author":"Tang F.","year":"2024","unstructured":"Tang F.; Wang X.; Liu T.; Wang H.; Wan Z.; Fu Q.; Zheng Z.; Aersi M.; Peng J.; Multiple fluorescences in situ hybridization status in excreted urine improve diagnostic efficacy for upper urinary tract urothelial carcinomas. Urol J  2024,21(2),107-113","journal-title":"Urol J"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.3390\/biomedicines10102560","volume":"10","author":"Sz\u00e9les \u00c1.","year":"2022","unstructured":"Sz\u00e9les \u00c1.; Kov\u00e1cs P.T.; Csizmarik A.; V\u00e1radi M.; Riesz P.; Fazekas T.; V\u00e1ncsa S.; Hegyi P.; Ol\u00e1h C.; Tschirdewahn S.; Darr C.; Krafft U.; Gr\u00fcnwald V.; Hadaschik B.; Horv\u00e1th O.; Nyir\u00e1dy P.; Szarvas T.; High pretreatment serum PD-L1 levels are associated with muscle invasion and shorter survival in upper tract urothelial carcinoma. Biomedicines  2022,10(10),2560","journal-title":"Biomedicines"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1097\/PAI.0000000000000957","volume":"30","author":"Ward M.","year":"2022","unstructured":"Ward M.; Albertson D.; Furtado L.V.; Deftereos G.; PD-L1 tumor cell expression in upper tract urothelial carcinomas is associated with higher pathologic stage. Appl Immunohistochem Mol Morphol  2022,30(1),56-61","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.3389\/fonc.2020.01400","volume":"10","author":"Lu Y.","year":"2020","unstructured":"Lu Y.; Kang J.; Luo Z.; Song Y.; Tian J.; Li Z.; Wang X.; Liu L.; Yang Y.; Liu X.; The prevalence and prognostic role of PD-L1 in upper tract urothelial carcinoma patients underwent radical nephroureterectomy: A systematic review and meta-analysis. Front Oncol  2020,10,1400","journal-title":"Front Oncol"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"4330","DOI":"10.1002\/cam4.1686","volume":"7","author":"Miyama Y.","year":"2018","unstructured":"Miyama Y.; Morikawa T.; Miyakawa J.; Koyama Y.; Kawai T.; Kume H.; Fukayama M.; The prognostic value of PD-L1 expression in upper tract urothelial carcinoma varies according to platelet count. Cancer Med  2018,7(9),4330-4338","journal-title":"Cancer Med"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0109298673339558250123110322","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/239227\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0109298673339558250123110322","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T04:21:32Z","timestamp":1770783692000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/239227\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":114,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0109298673339558250123110322","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Double blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2024-07-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-23","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}